BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36438219)

  • 21. HPV viral load in self-collected vaginal fluid samples as predictor for presence of cervical intraepithelial neoplasia.
    Berggrund M; Gustavsson I; Aarnio R; Hedlund-Lindberg J; Sanner K; Wikström I; Enroth S; Olovsson M; Gyllensten U
    Virol J; 2019 Nov; 16(1):146. PubMed ID: 31771594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
    Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
    PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
    Ovestad IT; Vennestrøm U; Andersen L; Gudlaugsson E; Munk AC; Malpica A; Feng W; Voorhorst F; Janssen EA; Baak JP
    Gynecol Oncol; 2011 Nov; 123(2):278-83. PubMed ID: 21835440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    Baasland I; Romundstad PR; Eide ML; Jonassen CM
    PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.
    Oštrbenk Valenčak A; Bertram A; Gröning A; Poljak M
    J Clin Virol; 2021 Jul; 140():104851. PubMed ID: 34020361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    El-Zein M; Bouten S; Louvanto K; Gilbert L; Gotlieb W; Hemmings R; Behr MA; Franco EL;
    Gynecol Oncol; 2018 Jun; 149(3):491-497. PubMed ID: 29678360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.
    Leinonen MK; Schee K; Jonassen CM; Lie AK; Nystrand CF; Rangberg A; Furre IE; Johansson MJ; Tropé A; Sjøborg KD; Castle PE; Nygård M
    J Clin Virol; 2018; 99-100():22-30. PubMed ID: 29289814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
    Tranberg M; Jensen JS; Bech BH; Andersen B
    BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
    Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
    Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a fluorescence-based multiplex genotyping method for simultaneous determination of human papillomavirus infections and viral loads.
    Sun Z; Zhang R; Liu Z; Liu C; Li X; Zhou W; Yang L; Ruan Q; Zhang X
    BMC Cancer; 2015 Nov; 15():860. PubMed ID: 26546160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.